Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
25.14
-1.31 (-4.95%)
At close: Mar 13, 2026, 4:00 PM EDT
24.75
-0.39 (-1.55%)
After-hours: Mar 13, 2026, 4:11 PM EDT
Septerna Employees
Septerna had 130 employees as of December 31, 2025. The number of employees increased by 55 or 73.33% compared to the previous year.
Employees
130
Change (1Y)
55
Growth (1Y)
73.33%
Revenue / Employee
$353,469
Profits / Employee
-$375,992
Market Cap
1.13B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 55 | 73.33% |
| Dec 31, 2024 | 75 | - | - |
| Sep 30, 2024 | 73 | - | - |
| Jun 30, 2024 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Immatics | 645 |
| EyePoint | 214 |
| Monte Rosa Therapeutics | 147 |
| Precigen | 143 |
| MoonLake Immunotherapeutics | 130 |
| Olema Pharmaceuticals | 122 |
| DBV Technologies | 117 |
| ORIC Pharmaceuticals | 104 |
SEPN News
- 4 days ago - Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 13 days ago - Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy - GlobeNewsWire
- 18 days ago - Septerna to Present at TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 4 weeks ago - Septerna Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting - GlobeNewsWire
- 2 months ago - Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer - GlobeNewsWire
- 3 months ago - Septerna to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Septerna to Participate in 8th Annual Evercore Healthcare Conference - GlobeNewsWire